retatrutide for sale canada Triple Agonist (GLP-1/GIP/GCG) Retatrutide Canada | GLP-3 Research
Description
The approval marked a milestone in OSA treatment: the first pharmacologic option shown to address contributing metabolic pathways of the condition rather than airway obstruction alone
Decreased appetite was reported by 11-31% among retatrutide-treated subjects (vs 9% placebo) in the obesity trial and by 10% (vs 2% placebo) in the diabetes trial [3,4]
Given the investigational nature of low-dose GLP-1 therapy for inflammation, identifying appropriate candidates requires careful clinical judgment and shared decision-making
Owens, L
